We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Progress in Therapeutic Cloning of Stem Cells

By Biotechdaily staff writers
Posted on 17 Dec 2004
Using new cloning techniques, scientists have taken a significant step toward the successful therapeutic cloning of nonhuman primate embryos. More...
Their progress was reported in the December 1, 2004, issue of Developmental Biology.

Researchers at the University of Pittsburgh (PA, USA) used newer cloning techniques developed by South Korean researchers, which included the "gentle squeeze” method they used to create the first cloned human embryonic stem cell line earlier in 2004.
It is the first time researchers have applied methods developed in South Korea to nonhuman primate eggs. The resulting cloned embryos progressed to the blastocyst stage, in which the embryo resembles a hollow, fluid-filled cavity surrounded by a single layer of cells. Called the inner cell mass, this layer contains embryonic stem cells. Growth of a cloned nonhuman primate egg to the blastocyst stage is further along the developmental spectrum than ever before, according to the researchers.

In a 2003 study, researchers using the techniques of nuclear transfer that had resulted in the cloning of Dolly, the sheep, found basic molecular obstacles that blocked normal cell development, such as absent or deficient proteins, chaotic mitotic spindle structures, and misaligned chromosomes. The most recent study appears to have broken that impasse. On the other hand, reproductive cloning remains elusive, and the Pittsburgh team indicates that the possibility of successful cloning of primates is even more remote than previously believed.

"What this shows is that the Korean method for efficient human somatic cell nuclear transfer is equally effective for nonhuman primates, allowing the further progress toward development of an animal model which parallels human biology,” remarked Dr. Gerald Schatten, Ph.D., director of the Pittsburgh Development Center at Magee-Womens Research Institute. "This approach does not violate federal or state laws, and allows for preclinical investigations that would not be ethically feasible in humans.”




Related Links:
U. Pittsburgh

New
Gold Member
Aspiration System
VACUSAFE
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
POC Immunoassay Analyzer
Procise DX
New
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.